Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

DiaMedica Therapeutics Q3 2026 Results: Net Loss of $11.3M, Loss Widens

DiaMedica Therapeutics reported a net loss of $31.5 million for the nine months ended September 30, 2026, driven by increased research and development expenses for its lead candidate DM199. The company's cash and marketable securities decreased to $34.9 million from $59.9 million at the end of 2025, reflecting ongoing clinical trial costs for preeclampsia and fetal growth restriction programs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-11.3-8.6
Net income-11.3-8.6
EPS (diluted, $ a share)$-0.21$-0.17

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: DMAC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

DiaMedica Therapeutics Inc.: key numbers

Share price
$8.38Close, Nov 17
Market cap
$452M
Shares outstanding
53.96MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from DiaMedica Therapeutics Inc.

All →
4:41 PM ET 8-K
Financial Results

DiaMedica Therapeutics Financial Results

DiaMedica Therapeutics reported Q3 2026 financial results and provided clinical updates on its DM199 programs. The company completed enrollment in the first two cohorts of its Phase 2 fetal growth restriction (FGR) trial and surpassed the 200-participant enrollment threshold for its ReMEDy2 Phase 2/3 acute ischemic stroke trial, with an interim analysis expected in Q1 2027.

Term
Q3 2026

“During the third quarter and recent weeks, we continued to advance DM199 across each of our clinical programs, including completing enrollment in the first two cohorts of our Phase 2 early-onset fetal growth restriction study and reaching the 200-participant enrollment threshold for the planned interim analysis of ReMEDy2.”

Rick Pauls, President and Chief Executive Officer

“Our clinical programs are providing important opportunities to evaluate the pharmacologic effects of DM199 across pregnancy-related vascular disorders and acute ischemic stroke.”

Julie Krop, MD, Chief Medical Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.